NOTE 8—ACCRUED LIABILITIES Accrued liabilities as of June 30, 2024 and December 31, 2023, are as follows (in thousands): | | | | | | | | | June 30, | | December 31, | | | 2024 | | 2023 | | | | | | | | Accrued licensing, milestone and royalty payments | | $ | 4,522 | | $ | 3,452 | Accrued clinical costs | | | 551 | | | 597 | Accrued compensation and board fees | | | 3,184 | | | 3,858 | Accrued manufacturing costs | | | 2,078 | | | 2,531 | Accrued sales reserves | | | 1,681 | | | 2,309 | Other | | | 772 | | | 419 | Total | | $ | 12,788 | | $ | 13,166 |
d
|